Not available outside of the UK & Ireland.

Biochem/physiol Actions

CRP is a hepatically derived pentraxin. It exists mainly as a pentamer in a cyclic structure with 5 identical 23-kD subunits in the blood. In addition to its role as an "acute phase" protein or first-line defense molecule against pathogenic organisms, baseline levels of CRP correlate positively to adverse cardiovascular events. CRP is therefore being considered a “risk factor” for cardiovascular disease. In humans, treatment with statin therapy reduces levels of both LDL-C and CRP, and concurrently there is a reduction in the number of cardiovascular events. A recent study suggests that patients with elevated basal levels of CRP are at an increased risk of diabetes, in addition to cardiovascular disease. A study of over 700 nurses showed that those in the highest quartile of trans fat consumption had blood levels of CRP that were 73% higher than those in the lowest quartile.

General description

SILu^™Prot CRP is a recombinant, stable isotope-labeled human CRP which incorporates [¹³C₆, ¹⁵N₄]-Arginine and ^[13C₆, ¹⁵N₂]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of CRP in mass-spectrometry. SILu^™Prot CRP is a protein consisting of 226 amino acids (including a C-terminal polyhistidine and FLAG^® tags), with a molecular weight of ~25 kDa.Suggested Quantitative Analysis Parameters (MRM settings provided for three suggested peptides)

Legal Information

SILu is a trademark of Sigma-Aldrich Co. LLC

FLAG is a registered trademark of Sigma-Aldrich Co. LLC

QTDMSRKAFVFPKESDTSYVSLKAPLTKPLKAFTVCLHFYTELSSTRGYSIFSYATKRQDNEILIFWSKDIGYSFTVGGSEILFEVPEVTVAPVHICTSWESASGIVEFWVDGKPRVRKSLKKGYTVGAEASIILGQEQDSFGGNFEGSQSLVGDIGNVNMWDFVLSPDEINTIYLGGPFSPNVLNWRALKYEVQGEVFTKPQLWPDYKDDDDKGHHHHHHHHGGQ

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.

Physical form

Supplied as a solution of phosphate buffered saline and 25% glycerol.